Survodutide vs Dihexa
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideCognitive Enhancement
Dihexa- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
- Half-Life
- ~7 days
- Unknown (limited pharmacokinetic data)
- Admin Route
- SubQ
- Oral, SubQ, Topical
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 5–10 mg
- Frequency
- Once weekly
- Daily
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
- Enhances memory and learning
- May reverse cognitive decline
- Improves neuroplasticity and executive function
- Long-lasting cognitive benefits from short courses
- Potential therapeutic agent for Alzheimer's
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Headache
- Irritability
- Brain fog during washout period
- Unknown long-term effects (insufficient data)
- Stacks With
- —
- —